HSDT stock touches 52-week low at $0.26 amid sharp annual decline

Helius Medical (TASE:BLWV) Technologies Inc. (NASDAQ:HSDT) stock has reached a new 52-week low, trading at $0.26. This latest price point underscores a challenging period for the medical technology company, which has seen its stock value plummet over the past year. According to InvestingPro data, the company’s financial health score stands at a concerning 1.42 (WEAK), with negative EBITDA of -$13.8M and revenue declining by -19.25% over the last twelve months. The 1-year change data paints a stark picture, with Helius Medical’s stock value eroding by an alarming -92.14%. This significant downturn reflects investor concerns and potentially broader issues within the company’s operations or market conditions affecting its performance. While the company maintains a current ratio of 1.58 and holds more cash than debt, InvestingPro analysis reveals concerning trends in cash burn rates and weak gross profit margins. As stakeholders and analysts observe this new low, the focus turns to the company’s strategies for recovery and stabilization in the face of such a steep decline. Discover 10 additional key insights about HSDT with an InvestingPro subscription, including detailed financial health metrics and expert analysis.

In other recent news, Helius Medical Technologies announced a 1-for-15 reverse stock split approved by shareholders, effective May 1, 2025, to maintain compliance with Nasdaq’s listing standards. This move will consolidate every 15 shares into one, reducing the total number of outstanding shares from approximately 7.9 million to about 0.5 million. Additionally, Helius secured $1.3 million through a private placement deal involving promissory notes and common shares, with Maxim Group LLC acting as the placement agent. The funds are intended for working capital and general corporate purposes.

In another development, Helius launched a subsidiary named Revelation Neuro, Inc., focusing on AI-powered brain-computer interface technology to enhance neurorehabilitation. The subsidiary aims to improve functional rehabilitation outcomes and plans to seek external funding for its operations. Meanwhile, Helius faces delisting from Nasdaq due to non-compliance with the Minimum Bid Price Requirement, having failed to meet the $1.00 threshold for 30 consecutive trading days. The company plans to appeal this decision, which will delay any delisting actions until a hearing is conducted.

Helius is also addressing its financial position by engaging with warrant holders to exercise their warrants at a reduced price, pending stockholder approval at the upcoming Annual Meeting. These recent developments highlight Helius Medical Technologies’ strategic efforts to navigate financial and operational challenges while advancing its technological initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.